A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination with Immune Checkpoint Inhibition in Participants with Locally Advanced or Metastatic Refractory Solid Tumors

Sponsor:

Normunity

Sponsor Study ID:

NRM-823-101

CTO #:

104241

NCT Number:

NCT07182149

Phase:

Early Phase I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Breast; Cervix Uteri; Esophagus; Lip, Oral Cavity and Pharynx; Lung; Other Digestive Organ; Other Female Genital; Ovary

Study Objectives:

To determine the safety and tolerability of NRM-823 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors. To determine the recommended dose(s) for expansion (RDE)s of NRM-823 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors. The RDE may be the maximum tolerated dose (MTD) or a biologically active dose below the MTD.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)